Caitong International Asset Management’s Briacell Therapeutics BCTX Stock Holding History

Caitong International Asset Management’s Portfolio BCTX Stock Details BCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$29	Buy	+7	New	+$33	﹤0.01%	2050

Other funds holding BCTX

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

LCM

LuminArx Capital Management New York $136M AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Caitong International Asset Management's BCTX Position: Q1 2026 in Review

Caitong International Asset Management opened a new position in Briacell Therapeutics (BCTX) in Q1 2026: 7 shares worth $29. The stake represents ﹤0.01% of the portfolio and ranks #2050 among its holdings.

16 funds tracked by Wall St. Rank hold BCTX as of Q1 2026.

Caitong International Asset Management held 7 shares of Briacell Therapeutics worth $29 as of Q1 2026.
Briacell Therapeutics was a new Caitong International Asset Management position in Q1 2026.
Briacell Therapeutics made up ﹤0.01% of Caitong International Asset Management's portfolio in Q1 2026, its #2050 holding.
16 funds tracked by Wall St. Rank held Briacell Therapeutics as of Q1 2026.

Based on Caitong International Asset Management's 13F filing for Q1 2026, filed 11 May 2026.